Treatment benefits of FDA-approved non-cleavable ADC (T-DM1) in HER2+ BC have motivated the development of different variants of ADC that can effectively release multiple cytotoxic agents (payloads or warheads) at the target. Here, ERBB2 is linked to breast cancer.